Implementing this strategy facilitates timely risk stratification and initiation of cardioprotective interventions (e.g., SGLT2 inhibitors, beta-blockers, and ACEIs), potentially attenuating disease progression, reducing heart failure incidence, and improving long-term outcomes in this high-risk population [10]. This evidence concerns the gene SLC5A2 and heart failure.